Company news
Lipocine Inc. (NASDAQ:LPCN) news
Every Lipocine Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
September 14, 2026
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
Lipocine : Appoints Michael J. Grissinger to Board of Directors
August 3, 2026
Lipocine Appoints Michael J. Grissinger to Board of Directors
August 3, 2026
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
June 4, 2026
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
May 19, 2026
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
May 18, 2026
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
May 7, 2026
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
April 2, 2026
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
March 10, 2026
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
February 18, 2026
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
January 20, 2026
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
January 12, 2026
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
December 16, 2025
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
November 18, 2025
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
November 6, 2025
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
November 4, 2025
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
September 30, 2025
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 5, 2025
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
August 26, 2025
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
August 5, 2025
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
June 26, 2025
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
June 23, 2025
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
June 9, 2025
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
May 22, 2025
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
May 14, 2025
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
May 8, 2025
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil
May 6, 2025
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
March 26, 2025
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
March 13, 2025
Lipocine Announces FDA Labeling Changes for Testosterone Products
March 12, 2025
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
February 6, 2025
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
December 17, 2024
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
November 18, 2024
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
November 7, 2024
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
October 31, 2024
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
October 10, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Count...
October 8, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
October 2, 2024
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
September 5, 2024
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
August 8, 2024
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
June 25, 2024
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
June 10, 2024
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
May 9, 2024
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
May 8, 2024
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
May 1, 2024
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
April 11, 2024
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
March 28, 2024
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
March 25, 2024
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
March 7, 2024